文献速递胸部肿瘤乳腺癌消化系统肿瘤

贝伐珠单抗在实体瘤中的作用:基于文献的随机试验荟萃分析

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.
PubMed 文献 · Eur J Cancer · 2017-02-24

该荟萃分析纳入在晚期实体瘤一线治疗中比较贝伐珠单抗方案与对照臂的随机试验,结果显示贝伐珠单抗方案显著改善总生存(HR 0.92)、无进展生存(HR 0.72)和缓解率(RR 1.38),但在乳腺癌中未见生存获益。

要点

  • 贝伐珠单抗方案较对照臂显著改善实体瘤总生存(HR 0.92)。
  • 无进展生存显著改善(HR 0.72),缓解率显著提高(RR 1.38)。
  • 乳腺癌中未见生存获益,作者认为需生物标志物分析筛选可能获益亚组。

核心结论

  • 贝伐珠单抗方案对晚期结直肠癌、肺癌、卵巢癌和肾癌的生存与缓解有显著效果。
  • 在贝伐珠单抗整体失败的癌种如乳腺癌中,作者认为需进行专门的生物标志物分析以筛选可能获得充分临床获益的合适患者亚组。

研究设计与样本

  • 基于文献的随机对照试验荟萃分析,遵循系统综述和荟萃分析报告条目指南。
  • 纳入所有在实体瘤一线治疗中比较贝伐珠单抗方案与对照臂(化疗、安慰剂或其他抗肿瘤药物)的随机试验(II期或III期)。
  • 主要终点为总生存,次要终点为无进展生存时间、缓解率和安全性。
  • 按不同肿瘤类型对所有终点进行亚组分析。

主要发现

  • 贝伐珠单抗方案较对照臂显著增加总生存(死亡风险比 HR 0.92,95%CI 0.88-0.95;P<0.0001)。
  • 贝伐珠单抗方案较对照臂显著改善无进展生存(HR 0.72,95%CI 0.67-0.78;P<0.00001)。
  • 贝伐珠单抗方案较对照臂显著提高缓解率(风险比 RR 1.38,95%CI 1.27-1.50;P<0.00001)。
  • 在整体实体瘤以及结直肠癌、肺癌、卵巢癌和肾癌作为单个适应症中均观察到上述获益。
  • 乳腺癌中未见生存获益。

临床怎么用

  • 作者认为在贝伐珠单抗整体失败的癌种如乳腺癌中,需进行专门的生物标志物分析以筛选可能获得充分临床获益的合适患者亚组。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bevacizumab is a humanised monoclonal antibody which blocks the binding of circulating vascular endothelial growth factor to its receptors. To date, the Food and Drug Administration has approved bevacizumab for the treatment of several solid tumours. To assess the impact of bevacizumab-based regimens on outcome in these advanced solid tumour types, we performed a meta-analysis. We included all of the randomised trials (phase II or III) where bevacizumab was tested in the first line setting compared with a control arm, including chemotherapy, placebo or other anti-neoplastic agents. METHODS: A literature-based meta-analysis of randomised controlled trials (RCTs) in accordance with the preferences for reported items in systematic reviews and meta-analyses guidelines were undertaken. The primary end-point considered was overall survival (OS). The secondary end-points were progression-free survival (PFS) time, response rate and safety. A subgroup analysis was performed to highlight any differences between studies in different tumour types for all end-points. RESULTS: The pooled analysis from RCTs on bevacizumab-based regimens revealed significantly increased OS (hazard ratio [HR] for death 0.92, 95% confidence interval [CI]: 0.88-0.95; P < 0.0001), PFS (HR: 0.72, 95% CI: 0.67-0.78; P < 0.00001) and response rate (risk ratio: 1.38, 95% CI: 1.27-1.50; P < 0.00001) compared to control arm in solid tumours overall and in colorectal, lung, ovarian and renal cancer as single indications. However, notably, no effect on survival was seen in breast cancer. CONCLUSION: This study confirmed that bevacizumab-based regimens result in a significant effect on survival and response in advanced colorectal, lung, ovarian and kidney cancer. In cancers where bevacizumab failed overall as in breast cancer, a dedicated biomarkers analysis is warranted to select the proper subgroup of patient that might have the adequate clinical benefit.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roviello G, Bachelot T, Hudis CA, et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Eur J Cancer. 2017. PMID: 28242502. doi:10.1016/j.ejca.2017.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。